IRIS
MORSIA, Erika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.212
AS - Asia 712
EU - Europa 649
SA - Sud America 280
AF - Africa 79
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2.934
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.176
IT - Italia 243
SG - Singapore 243
BR - Brasile 227
CN - Cina 192
RU - Federazione Russa 111
HK - Hong Kong 106
VN - Vietnam 90
DE - Germania 61
IE - Irlanda 49
CI - Costa d'Avorio 46
FR - Francia 32
GB - Regno Unito 28
NL - Olanda 26
AR - Argentina 24
FI - Finlandia 22
MX - Messico 21
SE - Svezia 20
AT - Austria 19
IN - India 18
MA - Marocco 13
PL - Polonia 12
ID - Indonesia 11
CA - Canada 10
BD - Bangladesh 8
EC - Ecuador 8
ES - Italia 8
JP - Giappone 8
TR - Turchia 8
AE - Emirati Arabi Uniti 6
CO - Colombia 6
PE - Perù 6
PH - Filippine 5
PY - Paraguay 5
SN - Senegal 5
ZA - Sudafrica 5
CZ - Repubblica Ceca 4
KR - Corea 4
EG - Egitto 3
LT - Lituania 3
TN - Tunisia 3
DO - Repubblica Dominicana 2
KZ - Kazakistan 2
MT - Malta 2
TW - Taiwan 2
TZ - Tanzania 2
UA - Ucraina 2
UZ - Uzbekistan 2
VE - Venezuela 2
AZ - Azerbaigian 1
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
CL - Cile 1
GI - Gibilterra 1
HN - Honduras 1
HU - Ungheria 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
SA - Arabia Saudita 1
TH - Thailandia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 2.934
Salva come PNG Salva come JPEG
Città #
Ashburn 227
Dallas 195
Singapore 144
Hong Kong 105
Boardman 86
Los Angeles 74
Beijing 49
Dublin 49
Abidjan 46
Ancona 41
Munich 40
Hefei 39
Chandler 38
New York 38
Ho Chi Minh City 34
Chicago 33
Buffalo 30
Moscow 24
Hanoi 19
Turin 19
São Paulo 18
The Dalles 18
Milan 17
Washington 17
Brooklyn 16
Salt Lake City 16
Denver 15
Rome 14
Turku 13
Amsterdam 11
Guangzhou 10
Santa Clara 10
Helsinki 9
London 9
Mexico City 9
Bari 8
Nuremberg 8
Orem 8
Stockholm 8
Chennai 7
Naples 7
San Francisco 7
Warsaw 7
Boston 6
Frankfurt am Main 6
Houston 6
Seattle 6
Shanghai 6
Tampa 6
Vienna 6
Dakar 5
Elk Grove Village 5
Falconara Marittima 5
Lima 5
Miami 5
Mumbai 5
North Charleston 5
Osimo 5
Rio de Janeiro 5
Wuhan 5
Atlanta 4
Bologna 4
Brasília 4
Campinas 4
Clifton 4
Columbus 4
Fortaleza 4
Haiphong 4
Lawrence 4
Paris 4
Perugia 4
Phoenix 4
Prague 4
Princeton 4
Querétaro 4
St Petersburg 4
Sterling 4
Tolentino 4
Toronto 4
Andria 3
Biên Hòa 3
Council Bluffs 3
Fairfield 3
Franca 3
Guarulhos 3
Guayaquil 3
Jiaxing 3
Johannesburg 3
Lucca 3
Magnesia ad Sipylum 3
Manchester 3
Montreal 3
Ninh Bình 3
Pasig-bo 3
Pesaro 3
Pisa 3
Poplar 3
Porto Alegre 3
Quảng Ninh 3
Ribeirão Preto 3
Totale 1.823
Salva come PNG Salva come JPEG
Nome #
Epidemiology of cutaneous T-cell lymphomas: state of the art and a focus on the Italian Marche region 136
Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report 120
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations 106
Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study 93
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas 92
A rare case of aCML associated with CNS involvement and with aggressive clinical course 91
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES 89
Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis 84
Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience 83
Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications 80
Prognosis in early stage cutaneous T-cell lymphoma treated with psoralen plus ultraviolet A irradiation and low-dose interferon-α: Long-term efficacy and survival according to conventional and emerging clinical endpoints 79
Anticoagulation and vessel recanalization in cirrhotic patients with splanchnic vein thrombosis: A multidisciplinary “real life” experience 78
Clinical Presentation, Risk Factors and Outcome of Splanchnic Venous Thrombosis: A Report on 305 Cases 75
Transfusion dependence is a risk factor for severe infections in myelodysplastic syndromes 71
Bone Marrow Adipose Tissue 71
Expression of Paraoxonase-2 in Different Stages of Cutaneous T Cell Lymphoma: Is It a Potential Biomarker for Aggressiveness? 69
AL amyloidosis: an overview on diagnosis, staging system, and treatment 68
Cutaneous T-cell lymphoma care across Europe: insights from the Horizon Project 67
Clinico-Pathological, Cytogenetic and Molecular Similarities and Differences between Primary and Secondary Cutaneous Lymphomas 66
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort 64
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 64
P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS? 63
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report 61
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights 60
Uncommon Presentation of Sarcoidosis with Severe Thrombocytopenia and Hemorrhagic Diathesis 59
Is There a Correlation Between Immune Thrombocytopenia and Immunoglobulin G4-Related Disease? 58
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study 57
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment 57
Epidemiology and Risk Factors for Infections in Myelodysplastic Syndromes 56
Long-Term Efficacy of Psoralen Plus Ultraviolet a Irradiation and Low-Dose Interferon-Alpha Therapy According to Conventional and Emerging Clinical Endopoints of Early Stage Cutaneous T Cell Lymphoma 53
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients 52
Myeloproliferative Neoplasms with Monocytosis 51
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management 51
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI) 45
WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic 44
Sequential Bispecific Antibodies in Functional and Clinical High Risk Multiple Myeloma, Manifesting with Extramedullary Disease at Relapse: A Case Report 44
Mutations and thrombosis in essential thrombocythemia 41
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study 39
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis 38
Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients 37
Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences 36
IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience 35
Pediatric primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: A retrospective analysis and review of the literature 34
Erythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort 33
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 33
Myelofibrosis: challenges for preclinical models and emerging therapeutic targets 33
Paraoxonase-2 in cutaneous T cell lymphomas. 32
Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real-world case series 28
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study 27
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea 27
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome 27
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients 25
Totale 3.082
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.252
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.252
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202230 7 1 0 0 0 1 3 2 0 3 6 7
2022/2023157 6 9 7 12 7 9 1 9 26 0 60 11
2023/2024378 37 12 38 44 57 54 11 13 3 28 15 66
2024/20251.011 66 66 38 19 31 53 96 24 171 55 193 199
2025/20261.506 213 252 295 384 311 51 0 0 0 0 0 0
Totale 3.082